nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—kidney cancer—urinary bladder cancer	0.678	1	CtDrD
Temsirolimus—ABCB1—Mitomycin—urinary bladder cancer	0.0409	0.324	CbGbCtD
Temsirolimus—CYP3A4—Thiotepa—urinary bladder cancer	0.0186	0.147	CbGbCtD
Temsirolimus—CYP3A5—Etoposide—urinary bladder cancer	0.0129	0.102	CbGbCtD
Temsirolimus—ABCB1—Gemcitabine—urinary bladder cancer	0.0118	0.0932	CbGbCtD
Temsirolimus—ABCB1—Cisplatin—urinary bladder cancer	0.00855	0.0677	CbGbCtD
Temsirolimus—ABCB1—Etoposide—urinary bladder cancer	0.0084	0.0665	CbGbCtD
Temsirolimus—ABCB1—Doxorubicin—urinary bladder cancer	0.00573	0.0454	CbGbCtD
Temsirolimus—ABCB1—Methotrexate—urinary bladder cancer	0.00555	0.044	CbGbCtD
Temsirolimus—CYP2D6—Doxorubicin—urinary bladder cancer	0.0054	0.0428	CbGbCtD
Temsirolimus—CYP3A4—Etoposide—urinary bladder cancer	0.00503	0.0399	CbGbCtD
Temsirolimus—CYP3A4—Doxorubicin—urinary bladder cancer	0.00343	0.0272	CbGbCtD
Temsirolimus—MTOR—prostate gland—urinary bladder cancer	0.00164	0.0666	CbGeAlD
Temsirolimus—FKBP1A—prostate gland—urinary bladder cancer	0.00148	0.0599	CbGeAlD
Temsirolimus—MTOR—seminal vesicle—urinary bladder cancer	0.00139	0.0563	CbGeAlD
Temsirolimus—CYP3A4—urine—urinary bladder cancer	0.00134	0.0545	CbGeAlD
Temsirolimus—CYP2D6—urine—urinary bladder cancer	0.00132	0.0537	CbGeAlD
Temsirolimus—FKBP1A—seminal vesicle—urinary bladder cancer	0.00125	0.0507	CbGeAlD
Temsirolimus—MTOR—epithelium—urinary bladder cancer	0.00121	0.0489	CbGeAlD
Temsirolimus—MTOR—smooth muscle tissue—urinary bladder cancer	0.00116	0.0472	CbGeAlD
Temsirolimus—MTOR—renal system—urinary bladder cancer	0.00112	0.0454	CbGeAlD
Temsirolimus—FKBP1A—epithelium—urinary bladder cancer	0.00109	0.044	CbGeAlD
Temsirolimus—FKBP1A—smooth muscle tissue—urinary bladder cancer	0.00105	0.0424	CbGeAlD
Temsirolimus—FKBP1A—renal system—urinary bladder cancer	0.00101	0.0408	CbGeAlD
Temsirolimus—FKBP1A—urethra—urinary bladder cancer	0.000989	0.0401	CbGeAlD
Temsirolimus—MTOR—female reproductive system—urinary bladder cancer	0.000896	0.0364	CbGeAlD
Temsirolimus—MTOR—vagina—urinary bladder cancer	0.000811	0.0329	CbGeAlD
Temsirolimus—FKBP1A—female reproductive system—urinary bladder cancer	0.000806	0.0327	CbGeAlD
Temsirolimus—FKBP1A—vagina—urinary bladder cancer	0.000729	0.0296	CbGeAlD
Temsirolimus—CYP3A5—prostate gland—urinary bladder cancer	0.000643	0.0261	CbGeAlD
Temsirolimus—MTOR—lymph node—urinary bladder cancer	0.000524	0.0213	CbGeAlD
Temsirolimus—FKBP1A—lymph node—urinary bladder cancer	0.000472	0.0191	CbGeAlD
Temsirolimus—CYP3A5—renal system—urinary bladder cancer	0.000438	0.0178	CbGeAlD
Temsirolimus—ABCB1—prostate gland—urinary bladder cancer	0.000342	0.0139	CbGeAlD
Temsirolimus—CYP3A4—renal system—urinary bladder cancer	0.000329	0.0133	CbGeAlD
Temsirolimus—CYP2D6—renal system—urinary bladder cancer	0.000324	0.0131	CbGeAlD
Temsirolimus—CYP3A5—vagina—urinary bladder cancer	0.000317	0.0129	CbGeAlD
Temsirolimus—ABCB1—seminal vesicle—urinary bladder cancer	0.000289	0.0117	CbGeAlD
Temsirolimus—CYP3A4—female reproductive system—urinary bladder cancer	0.000263	0.0107	CbGeAlD
Temsirolimus—CYP2D6—female reproductive system—urinary bladder cancer	0.000259	0.0105	CbGeAlD
Temsirolimus—ABCB1—epithelium—urinary bladder cancer	0.000251	0.0102	CbGeAlD
Temsirolimus—ABCB1—renal system—urinary bladder cancer	0.000233	0.00944	CbGeAlD
Temsirolimus—ABCB1—urethra—urinary bladder cancer	0.000229	0.00928	CbGeAlD
Temsirolimus—ABCB1—female reproductive system—urinary bladder cancer	0.000186	0.00756	CbGeAlD
Temsirolimus—ABCB1—vagina—urinary bladder cancer	0.000169	0.00684	CbGeAlD
Temsirolimus—ABCB1—lymph node—urinary bladder cancer	0.000109	0.00442	CbGeAlD
Temsirolimus—Dysphagia—Doxorubicin—urinary bladder cancer	6.97e-05	0.000615	CcSEcCtD
Temsirolimus—Pollakiuria—Epirubicin—urinary bladder cancer	6.96e-05	0.000614	CcSEcCtD
Temsirolimus—Body temperature increased—Fluorouracil—urinary bladder cancer	6.96e-05	0.000614	CcSEcCtD
Temsirolimus—Haematuria—Methotrexate—urinary bladder cancer	6.85e-05	0.000604	CcSEcCtD
Temsirolimus—Weight decreased—Epirubicin—urinary bladder cancer	6.82e-05	0.000602	CcSEcCtD
Temsirolimus—Dyspnoea—Etoposide—urinary bladder cancer	6.82e-05	0.000601	CcSEcCtD
Temsirolimus—Hyperglycaemia—Epirubicin—urinary bladder cancer	6.8e-05	0.0006	CcSEcCtD
Temsirolimus—Somnolence—Etoposide—urinary bladder cancer	6.8e-05	0.0006	CcSEcCtD
Temsirolimus—Epistaxis—Methotrexate—urinary bladder cancer	6.77e-05	0.000598	CcSEcCtD
Temsirolimus—Vomiting—Thiotepa—urinary bladder cancer	6.77e-05	0.000597	CcSEcCtD
Temsirolimus—Pneumonia—Epirubicin—urinary bladder cancer	6.76e-05	0.000596	CcSEcCtD
Temsirolimus—Infestation NOS—Epirubicin—urinary bladder cancer	6.72e-05	0.000593	CcSEcCtD
Temsirolimus—Infestation—Epirubicin—urinary bladder cancer	6.72e-05	0.000593	CcSEcCtD
Temsirolimus—Rash—Thiotepa—urinary bladder cancer	6.71e-05	0.000592	CcSEcCtD
Temsirolimus—Bronchitis—Doxorubicin—urinary bladder cancer	6.71e-05	0.000592	CcSEcCtD
Temsirolimus—Dermatitis—Thiotepa—urinary bladder cancer	6.7e-05	0.000592	CcSEcCtD
Temsirolimus—Headache—Thiotepa—urinary bladder cancer	6.67e-05	0.000588	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	6.66e-05	0.000588	CcSEcCtD
Temsirolimus—Decreased appetite—Etoposide—urinary bladder cancer	6.65e-05	0.000586	CcSEcCtD
Temsirolimus—Renal failure—Epirubicin—urinary bladder cancer	6.6e-05	0.000583	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Etoposide—urinary bladder cancer	6.6e-05	0.000582	CcSEcCtD
Temsirolimus—Body temperature increased—Cisplatin—urinary bladder cancer	6.6e-05	0.000582	CcSEcCtD
Temsirolimus—Fatigue—Etoposide—urinary bladder cancer	6.59e-05	0.000582	CcSEcCtD
Temsirolimus—Stomatitis—Epirubicin—urinary bladder cancer	6.55e-05	0.000578	CcSEcCtD
Temsirolimus—Pain—Etoposide—urinary bladder cancer	6.54e-05	0.000577	CcSEcCtD
Temsirolimus—Constipation—Etoposide—urinary bladder cancer	6.54e-05	0.000577	CcSEcCtD
Temsirolimus—Conjunctivitis—Epirubicin—urinary bladder cancer	6.53e-05	0.000576	CcSEcCtD
Temsirolimus—Urinary tract infection—Epirubicin—urinary bladder cancer	6.53e-05	0.000576	CcSEcCtD
Temsirolimus—Dysuria—Doxorubicin—urinary bladder cancer	6.52e-05	0.000575	CcSEcCtD
Temsirolimus—Neutropenia—Doxorubicin—urinary bladder cancer	6.52e-05	0.000575	CcSEcCtD
Temsirolimus—Hypersensitivity—Fluorouracil—urinary bladder cancer	6.49e-05	0.000572	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	6.48e-05	0.000572	CcSEcCtD
Temsirolimus—Pollakiuria—Doxorubicin—urinary bladder cancer	6.44e-05	0.000568	CcSEcCtD
Temsirolimus—Asthenia—Gemcitabine—urinary bladder cancer	6.42e-05	0.000567	CcSEcCtD
Temsirolimus—Haematuria—Epirubicin—urinary bladder cancer	6.41e-05	0.000565	CcSEcCtD
Temsirolimus—Pharyngitis—Methotrexate—urinary bladder cancer	6.4e-05	0.000564	CcSEcCtD
Temsirolimus—Urinary tract disorder—Methotrexate—urinary bladder cancer	6.37e-05	0.000562	CcSEcCtD
Temsirolimus—Epistaxis—Epirubicin—urinary bladder cancer	6.34e-05	0.000559	CcSEcCtD
Temsirolimus—Pruritus—Gemcitabine—urinary bladder cancer	6.33e-05	0.000559	CcSEcCtD
Temsirolimus—Nausea—Thiotepa—urinary bladder cancer	6.32e-05	0.000558	CcSEcCtD
Temsirolimus—Urethral disorder—Methotrexate—urinary bladder cancer	6.32e-05	0.000557	CcSEcCtD
Temsirolimus—Weight decreased—Doxorubicin—urinary bladder cancer	6.31e-05	0.000557	CcSEcCtD
Temsirolimus—Sinusitis—Epirubicin—urinary bladder cancer	6.3e-05	0.000556	CcSEcCtD
Temsirolimus—Hyperglycaemia—Doxorubicin—urinary bladder cancer	6.29e-05	0.000555	CcSEcCtD
Temsirolimus—Pneumonia—Doxorubicin—urinary bladder cancer	6.25e-05	0.000552	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Etoposide—urinary bladder cancer	6.25e-05	0.000552	CcSEcCtD
Temsirolimus—Pruritus—Fluorouracil—urinary bladder cancer	6.23e-05	0.00055	CcSEcCtD
Temsirolimus—Infestation NOS—Doxorubicin—urinary bladder cancer	6.22e-05	0.000549	CcSEcCtD
Temsirolimus—Infestation—Doxorubicin—urinary bladder cancer	6.22e-05	0.000549	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	6.16e-05	0.000544	CcSEcCtD
Temsirolimus—Hypersensitivity—Cisplatin—urinary bladder cancer	6.15e-05	0.000542	CcSEcCtD
Temsirolimus—Diarrhoea—Gemcitabine—urinary bladder cancer	6.13e-05	0.00054	CcSEcCtD
Temsirolimus—Renal failure—Doxorubicin—urinary bladder cancer	6.11e-05	0.000539	CcSEcCtD
Temsirolimus—Erythema multiforme—Methotrexate—urinary bladder cancer	6.09e-05	0.000538	CcSEcCtD
Temsirolimus—Stomatitis—Doxorubicin—urinary bladder cancer	6.06e-05	0.000535	CcSEcCtD
Temsirolimus—Rhinitis—Epirubicin—urinary bladder cancer	6.05e-05	0.000534	CcSEcCtD
Temsirolimus—Body temperature increased—Etoposide—urinary bladder cancer	6.04e-05	0.000533	CcSEcCtD
Temsirolimus—Abdominal pain—Etoposide—urinary bladder cancer	6.04e-05	0.000533	CcSEcCtD
Temsirolimus—Conjunctivitis—Doxorubicin—urinary bladder cancer	6.04e-05	0.000533	CcSEcCtD
Temsirolimus—Urinary tract infection—Doxorubicin—urinary bladder cancer	6.04e-05	0.000533	CcSEcCtD
Temsirolimus—Eye disorder—Methotrexate—urinary bladder cancer	6.02e-05	0.000531	CcSEcCtD
Temsirolimus—Diarrhoea—Fluorouracil—urinary bladder cancer	6.02e-05	0.000531	CcSEcCtD
Temsirolimus—Asthenia—Cisplatin—urinary bladder cancer	5.99e-05	0.000528	CcSEcCtD
Temsirolimus—Pharyngitis—Epirubicin—urinary bladder cancer	5.99e-05	0.000528	CcSEcCtD
Temsirolimus—Cardiac disorder—Methotrexate—urinary bladder cancer	5.98e-05	0.000528	CcSEcCtD
Temsirolimus—Urinary tract disorder—Epirubicin—urinary bladder cancer	5.96e-05	0.000526	CcSEcCtD
Temsirolimus—Oedema peripheral—Epirubicin—urinary bladder cancer	5.94e-05	0.000524	CcSEcCtD
Temsirolimus—Haematuria—Doxorubicin—urinary bladder cancer	5.93e-05	0.000523	CcSEcCtD
Temsirolimus—Connective tissue disorder—Epirubicin—urinary bladder cancer	5.93e-05	0.000523	CcSEcCtD
Temsirolimus—Urethral disorder—Epirubicin—urinary bladder cancer	5.91e-05	0.000522	CcSEcCtD
Temsirolimus—Epistaxis—Doxorubicin—urinary bladder cancer	5.86e-05	0.000517	CcSEcCtD
Temsirolimus—Angiopathy—Methotrexate—urinary bladder cancer	5.85e-05	0.000516	CcSEcCtD
Temsirolimus—Sinusitis—Doxorubicin—urinary bladder cancer	5.83e-05	0.000515	CcSEcCtD
Temsirolimus—Immune system disorder—Methotrexate—urinary bladder cancer	5.82e-05	0.000514	CcSEcCtD
Temsirolimus—Dizziness—Fluorouracil—urinary bladder cancer	5.82e-05	0.000514	CcSEcCtD
Temsirolimus—Mediastinal disorder—Methotrexate—urinary bladder cancer	5.81e-05	0.000513	CcSEcCtD
Temsirolimus—Chills—Methotrexate—urinary bladder cancer	5.78e-05	0.00051	CcSEcCtD
Temsirolimus—Diarrhoea—Cisplatin—urinary bladder cancer	5.71e-05	0.000504	CcSEcCtD
Temsirolimus—Erythema multiforme—Epirubicin—urinary bladder cancer	5.7e-05	0.000503	CcSEcCtD
Temsirolimus—Vomiting—Gemcitabine—urinary bladder cancer	5.69e-05	0.000502	CcSEcCtD
Temsirolimus—Mental disorder—Methotrexate—urinary bladder cancer	5.65e-05	0.000498	CcSEcCtD
Temsirolimus—Rash—Gemcitabine—urinary bladder cancer	5.64e-05	0.000498	CcSEcCtD
Temsirolimus—Dermatitis—Gemcitabine—urinary bladder cancer	5.64e-05	0.000498	CcSEcCtD
Temsirolimus—Eye disorder—Epirubicin—urinary bladder cancer	5.64e-05	0.000497	CcSEcCtD
Temsirolimus—Hypersensitivity—Etoposide—urinary bladder cancer	5.63e-05	0.000497	CcSEcCtD
Temsirolimus—Erythema—Methotrexate—urinary bladder cancer	5.61e-05	0.000495	CcSEcCtD
Temsirolimus—Malnutrition—Methotrexate—urinary bladder cancer	5.61e-05	0.000495	CcSEcCtD
Temsirolimus—Headache—Gemcitabine—urinary bladder cancer	5.61e-05	0.000495	CcSEcCtD
Temsirolimus—Cardiac disorder—Epirubicin—urinary bladder cancer	5.6e-05	0.000494	CcSEcCtD
Temsirolimus—Vomiting—Fluorouracil—urinary bladder cancer	5.6e-05	0.000494	CcSEcCtD
Temsirolimus—Rhinitis—Doxorubicin—urinary bladder cancer	5.6e-05	0.000494	CcSEcCtD
Temsirolimus—Rash—Fluorouracil—urinary bladder cancer	5.55e-05	0.00049	CcSEcCtD
Temsirolimus—Dermatitis—Fluorouracil—urinary bladder cancer	5.55e-05	0.000489	CcSEcCtD
Temsirolimus—Pharyngitis—Doxorubicin—urinary bladder cancer	5.54e-05	0.000489	CcSEcCtD
Temsirolimus—Headache—Fluorouracil—urinary bladder cancer	5.51e-05	0.000487	CcSEcCtD
Temsirolimus—Urinary tract disorder—Doxorubicin—urinary bladder cancer	5.51e-05	0.000486	CcSEcCtD
Temsirolimus—Oedema peripheral—Doxorubicin—urinary bladder cancer	5.5e-05	0.000485	CcSEcCtD
Temsirolimus—Dysgeusia—Methotrexate—urinary bladder cancer	5.49e-05	0.000485	CcSEcCtD
Temsirolimus—Asthenia—Etoposide—urinary bladder cancer	5.48e-05	0.000484	CcSEcCtD
Temsirolimus—Connective tissue disorder—Doxorubicin—urinary bladder cancer	5.48e-05	0.000484	CcSEcCtD
Temsirolimus—Angiopathy—Epirubicin—urinary bladder cancer	5.47e-05	0.000483	CcSEcCtD
Temsirolimus—Urethral disorder—Doxorubicin—urinary bladder cancer	5.47e-05	0.000483	CcSEcCtD
Temsirolimus—Immune system disorder—Epirubicin—urinary bladder cancer	5.45e-05	0.000481	CcSEcCtD
Temsirolimus—Mediastinal disorder—Epirubicin—urinary bladder cancer	5.44e-05	0.00048	CcSEcCtD
Temsirolimus—Back pain—Methotrexate—urinary bladder cancer	5.43e-05	0.000479	CcSEcCtD
Temsirolimus—Chills—Epirubicin—urinary bladder cancer	5.41e-05	0.000478	CcSEcCtD
Temsirolimus—Pruritus—Etoposide—urinary bladder cancer	5.41e-05	0.000477	CcSEcCtD
Temsirolimus—Nausea—Gemcitabine—urinary bladder cancer	5.32e-05	0.000469	CcSEcCtD
Temsirolimus—Vomiting—Cisplatin—urinary bladder cancer	5.31e-05	0.000468	CcSEcCtD
Temsirolimus—Mental disorder—Epirubicin—urinary bladder cancer	5.28e-05	0.000466	CcSEcCtD
Temsirolimus—Erythema multiforme—Doxorubicin—urinary bladder cancer	5.28e-05	0.000466	CcSEcCtD
Temsirolimus—Rash—Cisplatin—urinary bladder cancer	5.26e-05	0.000464	CcSEcCtD
Temsirolimus—Dermatitis—Cisplatin—urinary bladder cancer	5.26e-05	0.000464	CcSEcCtD
Temsirolimus—Malnutrition—Epirubicin—urinary bladder cancer	5.25e-05	0.000463	CcSEcCtD
Temsirolimus—Erythema—Epirubicin—urinary bladder cancer	5.25e-05	0.000463	CcSEcCtD
Temsirolimus—Diarrhoea—Etoposide—urinary bladder cancer	5.23e-05	0.000462	CcSEcCtD
Temsirolimus—Nausea—Fluorouracil—urinary bladder cancer	5.23e-05	0.000461	CcSEcCtD
Temsirolimus—Eye disorder—Doxorubicin—urinary bladder cancer	5.22e-05	0.00046	CcSEcCtD
Temsirolimus—Anaemia—Methotrexate—urinary bladder cancer	5.19e-05	0.000458	CcSEcCtD
Temsirolimus—Cardiac disorder—Doxorubicin—urinary bladder cancer	5.18e-05	0.000457	CcSEcCtD
Temsirolimus—Dysgeusia—Epirubicin—urinary bladder cancer	5.14e-05	0.000454	CcSEcCtD
Temsirolimus—Back pain—Epirubicin—urinary bladder cancer	5.08e-05	0.000448	CcSEcCtD
Temsirolimus—Angiopathy—Doxorubicin—urinary bladder cancer	5.06e-05	0.000447	CcSEcCtD
Temsirolimus—Dizziness—Etoposide—urinary bladder cancer	5.06e-05	0.000446	CcSEcCtD
Temsirolimus—Immune system disorder—Doxorubicin—urinary bladder cancer	5.04e-05	0.000445	CcSEcCtD
Temsirolimus—Mediastinal disorder—Doxorubicin—urinary bladder cancer	5.03e-05	0.000444	CcSEcCtD
Temsirolimus—Leukopenia—Methotrexate—urinary bladder cancer	5.02e-05	0.000443	CcSEcCtD
Temsirolimus—Chills—Doxorubicin—urinary bladder cancer	5.01e-05	0.000442	CcSEcCtD
Temsirolimus—Nausea—Cisplatin—urinary bladder cancer	4.96e-05	0.000437	CcSEcCtD
Temsirolimus—Cough—Methotrexate—urinary bladder cancer	4.9e-05	0.000432	CcSEcCtD
Temsirolimus—Mental disorder—Doxorubicin—urinary bladder cancer	4.89e-05	0.000431	CcSEcCtD
Temsirolimus—Convulsion—Methotrexate—urinary bladder cancer	4.86e-05	0.000429	CcSEcCtD
Temsirolimus—Vomiting—Etoposide—urinary bladder cancer	4.86e-05	0.000429	CcSEcCtD
Temsirolimus—Erythema—Doxorubicin—urinary bladder cancer	4.86e-05	0.000429	CcSEcCtD
Temsirolimus—Malnutrition—Doxorubicin—urinary bladder cancer	4.86e-05	0.000429	CcSEcCtD
Temsirolimus—Anaemia—Epirubicin—urinary bladder cancer	4.85e-05	0.000428	CcSEcCtD
Temsirolimus—Rash—Etoposide—urinary bladder cancer	4.82e-05	0.000425	CcSEcCtD
Temsirolimus—Dermatitis—Etoposide—urinary bladder cancer	4.82e-05	0.000425	CcSEcCtD
Temsirolimus—Headache—Etoposide—urinary bladder cancer	4.79e-05	0.000423	CcSEcCtD
Temsirolimus—Myalgia—Methotrexate—urinary bladder cancer	4.78e-05	0.000421	CcSEcCtD
Temsirolimus—Arthralgia—Methotrexate—urinary bladder cancer	4.78e-05	0.000421	CcSEcCtD
Temsirolimus—Chest pain—Methotrexate—urinary bladder cancer	4.78e-05	0.000421	CcSEcCtD
Temsirolimus—Dysgeusia—Doxorubicin—urinary bladder cancer	4.76e-05	0.00042	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	4.74e-05	0.000419	CcSEcCtD
Temsirolimus—Leukopenia—Epirubicin—urinary bladder cancer	4.7e-05	0.000415	CcSEcCtD
Temsirolimus—Back pain—Doxorubicin—urinary bladder cancer	4.7e-05	0.000415	CcSEcCtD
Temsirolimus—Cough—Epirubicin—urinary bladder cancer	4.58e-05	0.000404	CcSEcCtD
Temsirolimus—Anaphylactic shock—Methotrexate—urinary bladder cancer	4.58e-05	0.000404	CcSEcCtD
Temsirolimus—Convulsion—Epirubicin—urinary bladder cancer	4.55e-05	0.000401	CcSEcCtD
Temsirolimus—Infection—Methotrexate—urinary bladder cancer	4.55e-05	0.000401	CcSEcCtD
Temsirolimus—Nausea—Etoposide—urinary bladder cancer	4.54e-05	0.000401	CcSEcCtD
Temsirolimus—Hypertension—Epirubicin—urinary bladder cancer	4.53e-05	0.0004	CcSEcCtD
Temsirolimus—Nervous system disorder—Methotrexate—urinary bladder cancer	4.49e-05	0.000396	CcSEcCtD
Temsirolimus—Anaemia—Doxorubicin—urinary bladder cancer	4.49e-05	0.000396	CcSEcCtD
Temsirolimus—Thrombocytopenia—Methotrexate—urinary bladder cancer	4.48e-05	0.000396	CcSEcCtD
Temsirolimus—Chest pain—Epirubicin—urinary bladder cancer	4.47e-05	0.000394	CcSEcCtD
Temsirolimus—Arthralgia—Epirubicin—urinary bladder cancer	4.47e-05	0.000394	CcSEcCtD
Temsirolimus—Myalgia—Epirubicin—urinary bladder cancer	4.47e-05	0.000394	CcSEcCtD
Temsirolimus—Anxiety—Epirubicin—urinary bladder cancer	4.45e-05	0.000393	CcSEcCtD
Temsirolimus—Skin disorder—Methotrexate—urinary bladder cancer	4.45e-05	0.000392	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.44e-05	0.000392	CcSEcCtD
Temsirolimus—Anorexia—Methotrexate—urinary bladder cancer	4.36e-05	0.000385	CcSEcCtD
Temsirolimus—Leukopenia—Doxorubicin—urinary bladder cancer	4.35e-05	0.000384	CcSEcCtD
Temsirolimus—Anaphylactic shock—Epirubicin—urinary bladder cancer	4.29e-05	0.000378	CcSEcCtD
Temsirolimus—Oedema—Epirubicin—urinary bladder cancer	4.29e-05	0.000378	CcSEcCtD
Temsirolimus—Infection—Epirubicin—urinary bladder cancer	4.26e-05	0.000376	CcSEcCtD
Temsirolimus—Cough—Doxorubicin—urinary bladder cancer	4.24e-05	0.000374	CcSEcCtD
Temsirolimus—Convulsion—Doxorubicin—urinary bladder cancer	4.21e-05	0.000371	CcSEcCtD
Temsirolimus—Nervous system disorder—Epirubicin—urinary bladder cancer	4.2e-05	0.000371	CcSEcCtD
Temsirolimus—Thrombocytopenia—Epirubicin—urinary bladder cancer	4.2e-05	0.00037	CcSEcCtD
Temsirolimus—Hypertension—Doxorubicin—urinary bladder cancer	4.19e-05	0.00037	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	4.17e-05	0.000368	CcSEcCtD
Temsirolimus—Skin disorder—Epirubicin—urinary bladder cancer	4.16e-05	0.000367	CcSEcCtD
Temsirolimus—Insomnia—Methotrexate—urinary bladder cancer	4.14e-05	0.000365	CcSEcCtD
Temsirolimus—Arthralgia—Doxorubicin—urinary bladder cancer	4.14e-05	0.000365	CcSEcCtD
Temsirolimus—Myalgia—Doxorubicin—urinary bladder cancer	4.14e-05	0.000365	CcSEcCtD
Temsirolimus—Chest pain—Doxorubicin—urinary bladder cancer	4.14e-05	0.000365	CcSEcCtD
Temsirolimus—Anxiety—Doxorubicin—urinary bladder cancer	4.12e-05	0.000364	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	4.11e-05	0.000362	CcSEcCtD
Temsirolimus—Anorexia—Epirubicin—urinary bladder cancer	4.08e-05	0.00036	CcSEcCtD
Temsirolimus—Dyspnoea—Methotrexate—urinary bladder cancer	4.08e-05	0.00036	CcSEcCtD
Temsirolimus—Somnolence—Methotrexate—urinary bladder cancer	4.07e-05	0.000359	CcSEcCtD
Temsirolimus—Decreased appetite—Methotrexate—urinary bladder cancer	3.98e-05	0.000351	CcSEcCtD
Temsirolimus—Oedema—Doxorubicin—urinary bladder cancer	3.97e-05	0.00035	CcSEcCtD
Temsirolimus—Anaphylactic shock—Doxorubicin—urinary bladder cancer	3.97e-05	0.00035	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.95e-05	0.000349	CcSEcCtD
Temsirolimus—Fatigue—Methotrexate—urinary bladder cancer	3.95e-05	0.000348	CcSEcCtD
Temsirolimus—Infection—Doxorubicin—urinary bladder cancer	3.94e-05	0.000348	CcSEcCtD
Temsirolimus—Pain—Methotrexate—urinary bladder cancer	3.92e-05	0.000346	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.9e-05	0.000344	CcSEcCtD
Temsirolimus—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.89e-05	0.000343	CcSEcCtD
Temsirolimus—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.88e-05	0.000343	CcSEcCtD
Temsirolimus—Insomnia—Epirubicin—urinary bladder cancer	3.88e-05	0.000342	CcSEcCtD
Temsirolimus—Skin disorder—Doxorubicin—urinary bladder cancer	3.85e-05	0.00034	CcSEcCtD
Temsirolimus—Dyspnoea—Epirubicin—urinary bladder cancer	3.82e-05	0.000337	CcSEcCtD
Temsirolimus—Somnolence—Epirubicin—urinary bladder cancer	3.81e-05	0.000336	CcSEcCtD
Temsirolimus—Anorexia—Doxorubicin—urinary bladder cancer	3.78e-05	0.000333	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.74e-05	0.00033	CcSEcCtD
Temsirolimus—Decreased appetite—Epirubicin—urinary bladder cancer	3.73e-05	0.000329	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	3.7e-05	0.000326	CcSEcCtD
Temsirolimus—Fatigue—Epirubicin—urinary bladder cancer	3.69e-05	0.000326	CcSEcCtD
Temsirolimus—Pain—Epirubicin—urinary bladder cancer	3.66e-05	0.000323	CcSEcCtD
Temsirolimus—Constipation—Epirubicin—urinary bladder cancer	3.66e-05	0.000323	CcSEcCtD
Temsirolimus—Body temperature increased—Methotrexate—urinary bladder cancer	3.62e-05	0.000319	CcSEcCtD
Temsirolimus—Abdominal pain—Methotrexate—urinary bladder cancer	3.62e-05	0.000319	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.61e-05	0.000319	CcSEcCtD
Temsirolimus—Insomnia—Doxorubicin—urinary bladder cancer	3.59e-05	0.000316	CcSEcCtD
Temsirolimus—Dyspnoea—Doxorubicin—urinary bladder cancer	3.54e-05	0.000312	CcSEcCtD
Temsirolimus—Somnolence—Doxorubicin—urinary bladder cancer	3.52e-05	0.000311	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.5e-05	0.000309	CcSEcCtD
Temsirolimus—Decreased appetite—Doxorubicin—urinary bladder cancer	3.45e-05	0.000304	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.42e-05	0.000302	CcSEcCtD
Temsirolimus—Fatigue—Doxorubicin—urinary bladder cancer	3.42e-05	0.000302	CcSEcCtD
Temsirolimus—Pain—Doxorubicin—urinary bladder cancer	3.39e-05	0.000299	CcSEcCtD
Temsirolimus—Constipation—Doxorubicin—urinary bladder cancer	3.39e-05	0.000299	CcSEcCtD
Temsirolimus—Abdominal pain—Epirubicin—urinary bladder cancer	3.39e-05	0.000299	CcSEcCtD
Temsirolimus—Body temperature increased—Epirubicin—urinary bladder cancer	3.39e-05	0.000299	CcSEcCtD
Temsirolimus—Hypersensitivity—Methotrexate—urinary bladder cancer	3.37e-05	0.000298	CcSEcCtD
Temsirolimus—Asthenia—Methotrexate—urinary bladder cancer	3.29e-05	0.00029	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.24e-05	0.000286	CcSEcCtD
Temsirolimus—Pruritus—Methotrexate—urinary bladder cancer	3.24e-05	0.000286	CcSEcCtD
Temsirolimus—Hypersensitivity—Epirubicin—urinary bladder cancer	3.16e-05	0.000279	CcSEcCtD
Temsirolimus—Body temperature increased—Doxorubicin—urinary bladder cancer	3.13e-05	0.000277	CcSEcCtD
Temsirolimus—Abdominal pain—Doxorubicin—urinary bladder cancer	3.13e-05	0.000277	CcSEcCtD
Temsirolimus—Diarrhoea—Methotrexate—urinary bladder cancer	3.13e-05	0.000276	CcSEcCtD
Temsirolimus—Asthenia—Epirubicin—urinary bladder cancer	3.07e-05	0.000271	CcSEcCtD
Temsirolimus—Pruritus—Epirubicin—urinary bladder cancer	3.03e-05	0.000268	CcSEcCtD
Temsirolimus—Dizziness—Methotrexate—urinary bladder cancer	3.03e-05	0.000267	CcSEcCtD
Temsirolimus—Diarrhoea—Epirubicin—urinary bladder cancer	2.93e-05	0.000259	CcSEcCtD
Temsirolimus—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.92e-05	0.000258	CcSEcCtD
Temsirolimus—Vomiting—Methotrexate—urinary bladder cancer	2.91e-05	0.000257	CcSEcCtD
Temsirolimus—Rash—Methotrexate—urinary bladder cancer	2.89e-05	0.000255	CcSEcCtD
Temsirolimus—Dermatitis—Methotrexate—urinary bladder cancer	2.88e-05	0.000255	CcSEcCtD
Temsirolimus—Headache—Methotrexate—urinary bladder cancer	2.87e-05	0.000253	CcSEcCtD
Temsirolimus—Asthenia—Doxorubicin—urinary bladder cancer	2.84e-05	0.000251	CcSEcCtD
Temsirolimus—Dizziness—Epirubicin—urinary bladder cancer	2.83e-05	0.00025	CcSEcCtD
Temsirolimus—Pruritus—Doxorubicin—urinary bladder cancer	2.81e-05	0.000248	CcSEcCtD
Temsirolimus—Vomiting—Epirubicin—urinary bladder cancer	2.72e-05	0.00024	CcSEcCtD
Temsirolimus—Nausea—Methotrexate—urinary bladder cancer	2.72e-05	0.00024	CcSEcCtD
Temsirolimus—Diarrhoea—Doxorubicin—urinary bladder cancer	2.71e-05	0.000239	CcSEcCtD
Temsirolimus—Rash—Epirubicin—urinary bladder cancer	2.7e-05	0.000238	CcSEcCtD
Temsirolimus—Dermatitis—Epirubicin—urinary bladder cancer	2.7e-05	0.000238	CcSEcCtD
Temsirolimus—Headache—Epirubicin—urinary bladder cancer	2.68e-05	0.000237	CcSEcCtD
Temsirolimus—Dizziness—Doxorubicin—urinary bladder cancer	2.62e-05	0.000231	CcSEcCtD
Temsirolimus—Nausea—Epirubicin—urinary bladder cancer	2.55e-05	0.000225	CcSEcCtD
Temsirolimus—Vomiting—Doxorubicin—urinary bladder cancer	2.52e-05	0.000222	CcSEcCtD
Temsirolimus—Rash—Doxorubicin—urinary bladder cancer	2.5e-05	0.000221	CcSEcCtD
Temsirolimus—Dermatitis—Doxorubicin—urinary bladder cancer	2.5e-05	0.00022	CcSEcCtD
Temsirolimus—Headache—Doxorubicin—urinary bladder cancer	2.48e-05	0.000219	CcSEcCtD
Temsirolimus—Nausea—Doxorubicin—urinary bladder cancer	2.36e-05	0.000208	CcSEcCtD
Temsirolimus—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.05e-05	0.000356	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.04e-05	0.000354	CbGpPWpGaD
Temsirolimus—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.03e-05	0.000351	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—S100B—urinary bladder cancer	2.01e-05	0.000348	CbGpPWpGaD
Temsirolimus—MTOR—Disease—JAG1—urinary bladder cancer	2e-05	0.000345	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	2e-05	0.000345	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—urinary bladder cancer	1.98e-05	0.000342	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—NAT2—urinary bladder cancer	1.95e-05	0.000337	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	1.94e-05	0.000337	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.94e-05	0.000336	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTO2—urinary bladder cancer	1.94e-05	0.000335	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NAT1—urinary bladder cancer	1.94e-05	0.000335	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	1.92e-05	0.000333	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.92e-05	0.000332	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—EGFR—urinary bladder cancer	1.89e-05	0.000328	CbGpPWpGaD
Temsirolimus—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.89e-05	0.000327	CbGpPWpGaD
Temsirolimus—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.86e-05	0.000322	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CREBBP—urinary bladder cancer	1.86e-05	0.000322	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IFNA2—urinary bladder cancer	1.85e-05	0.00032	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	1.82e-05	0.000316	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NAT1—urinary bladder cancer	1.82e-05	0.000316	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NCOR1—urinary bladder cancer	1.81e-05	0.000313	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—KRAS—urinary bladder cancer	1.79e-05	0.00031	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CREBBP—urinary bladder cancer	1.78e-05	0.000308	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CDH1—urinary bladder cancer	1.77e-05	0.000307	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	1.77e-05	0.000307	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—S100B—urinary bladder cancer	1.75e-05	0.000303	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—urinary bladder cancer	1.7e-05	0.000293	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—RRM2—urinary bladder cancer	1.68e-05	0.000291	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	1.67e-05	0.000289	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.65e-05	0.000285	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.62e-05	0.000281	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—RHOA—urinary bladder cancer	1.61e-05	0.000279	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TERT—urinary bladder cancer	1.6e-05	0.000276	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.59e-05	0.000276	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.59e-05	0.000275	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RBX1—urinary bladder cancer	1.56e-05	0.00027	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—ERBB2—urinary bladder cancer	1.56e-05	0.00027	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ENO2—urinary bladder cancer	1.56e-05	0.000269	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	1.56e-05	0.000269	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TYMP—urinary bladder cancer	1.55e-05	0.000269	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—HRAS—urinary bladder cancer	1.52e-05	0.000263	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	1.51e-05	0.000261	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.51e-05	0.000261	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	1.5e-05	0.00026	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ERBB2—urinary bladder cancer	1.5e-05	0.000259	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—ERBB2—urinary bladder cancer	1.49e-05	0.000258	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TSC1—urinary bladder cancer	1.47e-05	0.000254	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.47e-05	0.000254	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—FGFR3—urinary bladder cancer	1.46e-05	0.000253	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTGS2—urinary bladder cancer	1.46e-05	0.000252	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NCOR1—urinary bladder cancer	1.45e-05	0.000252	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.44e-05	0.000248	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ESR1—urinary bladder cancer	1.42e-05	0.000246	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.42e-05	0.000246	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NAT2—urinary bladder cancer	1.41e-05	0.000243	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—JAG1—urinary bladder cancer	1.4e-05	0.000242	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.39e-05	0.00024	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.39e-05	0.00024	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.38e-05	0.000239	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERCC2—urinary bladder cancer	1.37e-05	0.000237	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CDKN1A—urinary bladder cancer	1.33e-05	0.000231	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—PTEN—urinary bladder cancer	1.33e-05	0.00023	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.32e-05	0.000229	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.28e-05	0.000222	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MTHFR—urinary bladder cancer	1.28e-05	0.000222	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TERT—urinary bladder cancer	1.28e-05	0.000222	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CDKN1A—urinary bladder cancer	1.28e-05	0.000221	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—PTEN—urinary bladder cancer	1.28e-05	0.000221	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CDKN1A—urinary bladder cancer	1.27e-05	0.00022	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—FGFR3—urinary bladder cancer	1.27e-05	0.00022	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—PTEN—urinary bladder cancer	1.27e-05	0.00022	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EP300—urinary bladder cancer	1.27e-05	0.000219	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.26e-05	0.000218	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—NQO1—urinary bladder cancer	1.25e-05	0.000217	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.25e-05	0.000216	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—SRC—urinary bladder cancer	1.23e-05	0.000213	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IGF1—urinary bladder cancer	1.23e-05	0.000213	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—RRM2—urinary bladder cancer	1.21e-05	0.00021	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EP300—urinary bladder cancer	1.21e-05	0.00021	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.19e-05	0.000206	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.19e-05	0.000206	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—SRC—urinary bladder cancer	1.18e-05	0.000205	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—SRC—urinary bladder cancer	1.18e-05	0.000204	CbGpPWpGaD
Temsirolimus—MTOR—Disease—FGFR3—urinary bladder cancer	1.18e-05	0.000203	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.17e-05	0.000203	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.15e-05	0.000199	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—S100B—urinary bladder cancer	1.13e-05	0.000196	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—RHOA—urinary bladder cancer	1.13e-05	0.000195	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.13e-05	0.000195	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	1.12e-05	0.000195	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ENO2—urinary bladder cancer	1.12e-05	0.000195	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.11e-05	0.000191	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.09e-05	0.000189	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	1.09e-05	0.000189	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CREBBP—urinary bladder cancer	1.08e-05	0.000188	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EGFR—urinary bladder cancer	1.08e-05	0.000187	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDH1—urinary bladder cancer	1.08e-05	0.000186	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.07e-05	0.000186	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.06e-05	0.000184	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.06e-05	0.000184	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MYC—urinary bladder cancer	1.06e-05	0.000183	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	1.05e-05	0.000181	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.04e-05	0.000181	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—EGFR—urinary bladder cancer	1.04e-05	0.00018	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EGFR—urinary bladder cancer	1.03e-05	0.000179	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—KRAS—urinary bladder cancer	1.02e-05	0.000177	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NCOR1—urinary bladder cancer	1.02e-05	0.000176	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CREBBP—urinary bladder cancer	1e-05	0.000173	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1e-05	0.000173	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CXCL8—urinary bladder cancer	9.9e-06	0.000171	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	9.83e-06	0.00017	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—KRAS—urinary bladder cancer	9.8e-06	0.00017	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—KRAS—urinary bladder cancer	9.76e-06	0.000169	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—TYMS—urinary bladder cancer	9.72e-06	0.000168	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	9.61e-06	0.000166	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	9.61e-06	0.000166	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL2—urinary bladder cancer	9.46e-06	0.000164	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	9.46e-06	0.000164	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	9.28e-06	0.000161	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCND1—urinary bladder cancer	9.22e-06	0.00016	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—GPX1—urinary bladder cancer	9.2e-06	0.000159	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—RRM2—urinary bladder cancer	9.16e-06	0.000159	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ERBB2—urinary bladder cancer	9.08e-06	0.000157	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NQO1—urinary bladder cancer	9.06e-06	0.000157	CbGpPWpGaD
Temsirolimus—MTOR—Disease—RHOA—urinary bladder cancer	9.05e-06	0.000157	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	9.04e-06	0.000156	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	9.03e-06	0.000156	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TERT—urinary bladder cancer	8.97e-06	0.000155	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MMP9—urinary bladder cancer	8.95e-06	0.000155	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.92e-06	0.000154	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—PTEN—urinary bladder cancer	8.9e-06	0.000154	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HRAS—urinary bladder cancer	8.67e-06	0.00015	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—RRM2—urinary bladder cancer	8.63e-06	0.000149	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	8.49e-06	0.000147	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EP300—urinary bladder cancer	8.49e-06	0.000147	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HPGDS—urinary bladder cancer	8.48e-06	0.000147	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ENO2—urinary bladder cancer	8.48e-06	0.000147	CbGpPWpGaD
Temsirolimus—MTOR—Disease—ERBB2—urinary bladder cancer	8.38e-06	0.000145	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HRAS—urinary bladder cancer	8.33e-06	0.000144	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HRAS—urinary bladder cancer	8.29e-06	0.000144	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SRC—urinary bladder cancer	8.25e-06	0.000143	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FGFR3—urinary bladder cancer	8.23e-06	0.000142	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTT1—urinary bladder cancer	8.23e-06	0.000142	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL2—urinary bladder cancer	8.23e-06	0.000142	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTGS2—urinary bladder cancer	8.19e-06	0.000142	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ESR1—urinary bladder cancer	8e-06	0.000138	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	7.99e-06	0.000138	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ENO2—urinary bladder cancer	7.99e-06	0.000138	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CDKN1A—urinary bladder cancer	7.76e-06	0.000134	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	7.75e-06	0.000134	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—PTEN—urinary bladder cancer	7.74e-06	0.000134	CbGpPWpGaD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.7e-06	0.000133	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	7.56e-06	0.000131	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MYC—urinary bladder cancer	7.39e-06	0.000128	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EP300—urinary bladder cancer	7.38e-06	0.000128	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—urinary bladder cancer	7.23e-06	0.000125	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TYMP—urinary bladder cancer	7.23e-06	0.000125	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—SRC—urinary bladder cancer	7.18e-06	0.000124	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CDKN1A—urinary bladder cancer	7.16e-06	0.000124	CbGpPWpGaD
Temsirolimus—MTOR—Disease—PTEN—urinary bladder cancer	7.15e-06	0.000124	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—TYMS—urinary bladder cancer	7.03e-06	0.000122	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CREBBP—urinary bladder cancer	7.01e-06	0.000121	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	6.94e-06	0.00012	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	6.94e-06	0.00012	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IGF1—urinary bladder cancer	6.92e-06	0.00012	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PPARG—urinary bladder cancer	6.89e-06	0.000119	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NQO1—urinary bladder cancer	6.84e-06	0.000118	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—KRAS—urinary bladder cancer	6.83e-06	0.000118	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EP300—urinary bladder cancer	6.82e-06	0.000118	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—GPX1—urinary bladder cancer	6.65e-06	0.000115	CbGpPWpGaD
Temsirolimus—MTOR—Disease—SRC—urinary bladder cancer	6.63e-06	0.000115	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	6.61e-06	0.000114	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NAT2—urinary bladder cancer	6.54e-06	0.000113	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	6.53e-06	0.000113	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NQO1—urinary bladder cancer	6.44e-06	0.000112	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RHOA—urinary bladder cancer	6.34e-06	0.00011	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—urinary bladder cancer	6.29e-06	0.000109	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	6.14e-06	0.000106	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—urinary bladder cancer	6.07e-06	0.000105	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—KRAS—urinary bladder cancer	5.94e-06	0.000103	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MYC—urinary bladder cancer	5.94e-06	0.000103	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—ERBB2—urinary bladder cancer	5.87e-06	0.000102	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—urinary bladder cancer	5.81e-06	0.000101	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HRAS—urinary bladder cancer	5.81e-06	0.000101	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTP1—urinary bladder cancer	5.7e-06	9.87e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.64e-06	9.77e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CXCL8—urinary bladder cancer	5.57e-06	9.63e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—KRAS—urinary bladder cancer	5.49e-06	9.5e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	5.42e-06	9.37e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	5.37e-06	9.3e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL2—urinary bladder cancer	5.32e-06	9.2e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—TYMS—urinary bladder cancer	5.3e-06	9.18e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NCOR1—urinary bladder cancer	5.24e-06	9.07e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GSTM1—urinary bladder cancer	5.24e-06	9.07e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	5.23e-06	9.04e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ENO2—urinary bladder cancer	5.23e-06	9.04e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCND1—urinary bladder cancer	5.18e-06	8.97e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	5.07e-06	8.77e-05	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HRAS—urinary bladder cancer	5.05e-06	8.74e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MMP9—urinary bladder cancer	5.03e-06	8.71e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—GPX1—urinary bladder cancer	5.02e-06	8.69e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CDKN1A—urinary bladder cancer	5.02e-06	8.68e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—PTEN—urinary bladder cancer	5e-06	8.66e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—TYMS—urinary bladder cancer	5e-06	8.65e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PPARG—urinary bladder cancer	4.98e-06	8.61e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	4.94e-06	8.55e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	4.94e-06	8.55e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.93e-06	8.53e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	4.78e-06	8.27e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EP300—urinary bladder cancer	4.77e-06	8.26e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—GPX1—urinary bladder cancer	4.73e-06	8.18e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PTEN—urinary bladder cancer	4.72e-06	8.17e-05	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HRAS—urinary bladder cancer	4.66e-06	8.07e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	4.64e-06	8.04e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SRC—urinary bladder cancer	4.64e-06	8.03e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—MTHFR—urinary bladder cancer	4.63e-06	8.02e-05	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—EP300—urinary bladder cancer	4.5e-06	7.8e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	4.36e-06	7.55e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NQO1—urinary bladder cancer	4.21e-06	7.29e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MYC—urinary bladder cancer	4.16e-06	7.2e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—urinary bladder cancer	4.07e-06	7.04e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	3.92e-06	6.78e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—KRAS—urinary bladder cancer	3.84e-06	6.65e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.76e-06	6.5e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.61e-06	6.24e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PPARG—urinary bladder cancer	3.54e-06	6.12e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.51e-06	6.08e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—urinary bladder cancer	3.42e-06	5.91e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PTEN—urinary bladder cancer	3.41e-06	5.91e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.4e-06	5.88e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.27e-06	5.65e-05	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HRAS—urinary bladder cancer	3.27e-06	5.65e-05	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—EP300—urinary bladder cancer	3.26e-06	5.64e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.23e-06	5.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.23e-06	5.59e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.09e-06	5.35e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.04e-06	5.25e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.95e-06	5.11e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.85e-06	4.94e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.78e-06	4.82e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.58e-06	4.46e-05	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—EP300—urinary bladder cancer	2.46e-06	4.25e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.43e-06	4.2e-05	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.32e-06	4.01e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.31e-06	4e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.22e-06	3.85e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.82e-06	3.15e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.59e-06	2.75e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.51e-06	2.62e-05	CbGpPWpGaD
